# NCT03052608 (NCT03052608)

> A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03052608
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Lorlatinib; Crizotinib
- Enrollment: 296
- Primary outcome: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment

## Commentary we found

- X threads: 9

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03052608

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03052608", "email": "<work email>"}; the inbox owner confirms by the emailed link.